Detalles de la búsqueda
1.
Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non-small cell lung cancer.
Cancer Sci;
115(5): 1656-1664, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38450844
2.
Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients.
Target Oncol;
19(3): 411-421, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38467958
3.
Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50.
Front Immunol;
15: 1348034, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38464519
4.
Comparing Three Different Anti-Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study.
JTO Clin Res Rep;
5(3): 100644, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38444594
5.
AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells.
Cancer Lett;
587: 216692, 2024 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38342232
6.
Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer.
Oncologist;
29(5): e681-e689, 2024 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38241181
7.
Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells.
Mol Cancer Ther;
23(2): 212-222, 2024 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37802502
8.
The landscape of immune therapy in vulnerable patients with advanced non-small cell lung cancer: a narrative review.
Transl Lung Cancer Res;
12(11): 2310-2321, 2023 Nov 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38090528
9.
Recurrence of Large-Vessel Vasculitis Induced by Multiple Types of Granulocyte Colony-Stimulating Factor Preparation in Patient with Large-Cell Neuroendocrine Lung Carcinoma: A Case Report.
Case Rep Oncol;
16(1): 771-778, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37900825
10.
A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: The SPIRAL-RT study.
Eur J Cancer;
195: 113373, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37890349
11.
Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status.
Target Oncol;
18(6): 915-925, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37902896
12.
Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study.
Target Oncol;
18(5): 657-665, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37610516
13.
Endobronchial metastasis of hepatocellular carcinoma treated with Lenvatinib: A case report.
Respirol Case Rep;
11(9): e01208, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37614813
14.
Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors.
JTO Clin Res Rep;
4(6): 100525, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37426308
15.
Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
JAMA Netw Open;
6(7): e2322915, 2023 07 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37432682
16.
Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study).
Ther Adv Med Oncol;
15: 17588359231177022, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37333903
17.
Venetoclax and Azacitidine in the Treatment of NPM1-Mutated Donor Cell-Derived Leukemia in a Patient With Fanconi Anemia: Case Report and Literature Review.
JCO Precis Oncol;
7: e2200693, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37315262
18.
Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum-Etoposide Chemotherapy.
Drugs Aging;
40(6): 563-571, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37145245
19.
Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study.
JTO Clin Res Rep;
4(4): 100493, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37025120
20.
TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study.
JTO Clin Res Rep;
4(4): 100494, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37020925